References
- GalerBSCoyleNPasternakGWPortenoyRKIndividual variability in the response to different opioids: report of five casesPain199249187911375728
- ChouRFanciulloGJFinePGOpioid treatment guidelines: clinical guidelines for the use of chronic opioid therapy in chronic noncancer painJ Pain200910211313019187889
- FinePGPortenoyRKAd Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing “best practices” for opioid rotation: conclusions of an expert panelJ Pain Symptom Manage200938341842519735902
- SlatkinNEOpioid switching and rotation in primary care: implementation and clinical utilityCurr Med Res Opin20092592133215019601703
- MercadanteSOpioid rotation for cancer pain: rationale and clinical aspectsCancer19998691856186610547561
- PanLXuJYuRXuMMPanYXPasternakGWIdentification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, OprmNeuroscience2005133120922015893644
- PasternakGWIncomplete cross tolerance and multiple mu opioid peptide receptorsTrends Pharmacol Sci2001222677011166849
- EckhardtKLiSAmmonSSchänzleGMikusGEichelbaumMSame incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formationPain1998761–227339696456
- RussellRDChangKJAlternated delta and mu receptor activation: a stratagem for limiting opioid tolerancePain19893633813892540475
- Exalgo [package insert]Hazelwood, MOMallinckrodt Inc, a Covidien company2010
- Embeda [package insert]Bristol, TNKing Pharmaceuticals2009
- Oxycontin [package insert]Stamford, CTPurdue Pharma LP2010
- Avinza [package insert]Bristol, TNKing Pharmaceuticals Inc2008
- OpanaER [package insert]Chadds Ford, PAEndo Pharmaceuticals Inc2008
- Kadian [package insert]Morristown, NJActavis Elizabeth LLC2010
- MS Contin [package insert]Stamford, CTPurdue Pharma LP2009
- Oramorph SR [package insert]Newport, KYXanodyne Pharmaceuticals Inc2006
- Duragesic [package insert]Raritan, NJPriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc2006
- NucyntaER[package insert]Titusville, NJJanssen Pharmaceuticals Inc2011
- GourlayDLHeitHAAlmahreziAUniversal precautions in pain medicine: a rational approach to the treatment of chronic painPain Med20056210711215773874
- BohnertASValensteinMBairMJAssociation between opioid prescribing patterns and opioid overdose-related deathsJAMA2011305131315132121467284
- DunnKMSaundersKWRutterCMOpioid prescriptions for chronic pain and overdose: a cohort studyAnn Intern Med20101522859220083827
- HaleMKhanAKutchMLiSOnce-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back painCurr Med Res Opin20102661505151820429852
- PalangioMNorthfeltDWPortenoyRKDose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant painJ Pain Symptom Manage200223535536812007754
- US Food and Drug AdministrationQuestions and answers about oral prescription acetaminophen products to be limited to 325 mg per dosage unit Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm239871.htm. Accessed October 7, 2011.
- US Food and Drug AdministrationAcetaminophen overdose and liver injury – background and options for reducing injury Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM164897.pdf. Accessed November 1, 2011.
- Quang-CantagrelNDWallaceMSMagnusonSKOpioid substitution to improve the effectiveness of chronic noncancer pain control: a chart reviewAnesth Analg200090493393710735802
- KnotkovaHFinePGPortenoyRKOpioid rotation: the science and the limitations of the equianalgesic dose tableJ Pain Symptom Manage200938342643919735903
- MahlerDLForrestWHJrRelative analgesic potencies of morphine and hydromorphone in postoperative painAnesthesiology197542560260748347
- SmithHFinePPassikSOpioid Risk Management: Tools and TipsNew YorkOxford University Press Inc2009
- Parsells KellyJCookSFKaufmanDWAndersonTRosenbergLMitchellAAPrevalence and characteristics of opioid use in the US adult populationPain2008138350751318342447
- SmithHSOpioid metabolismMayo Clin Proc200984761362419567715
- ConeEJDarwinWDGorodetzkyCWTanTComparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dogDrug Metab Dispos19786448849328931
- OttonSVSchadelMCheungSWKaplanHLBustoUESellersEMCYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphoneClin Pharmacol Ther19935454634727693389
- LalovicBPhillipsBRislerLLHowaldWShenDDQuantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomesDrug Metab Dispos200432444745415039299
- ManchikantiLSinghVCarawayDLBenyaminRMBreakthrough pain in chronic non-cancer pain: fact, fiction, or abusePain Physician2011142E103E11721412376
- PortenoyRKBennettDSRauckRPrevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer painJ Pain20067858359116885015
- PortenoyRKBrunsDShoemakerBShoemakerSABreakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristicsJ Opioid Manag2010629710820481174
- US Food and Drug AdministrationInformation for healthcare professionals: methadone hydrochlorideRockville, MDUS Food and Drug Administration2006
- BrueraEPereiraJWatanabeSBelzileMKuehnNHansonJOpioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphineCancer19967848528578756381
- DavisAMInturrisiCEd-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesiaJ Pharmacol Exp Ther199928921048105310215686
- WarnerMChenLHMakucDMIncrease in fatal poisonings involving opioid analgesics in the United States, 1999–2006NCHS Data Brief.2009221819796521
- SavageSRJoransonDECovingtonECSchnollSHHeitHAGilsonAMDefinitions related to the medical use of opioids: evolution towards universal agreementJ Pain Symptom Manage200326165566712850648
- GilsonAMJoransonDEMaurerMAImproving state pain policies: recent progress and continuing opportunitiesCA Cancer J Clin200757634135317989129
- US Food and Drug AdministrationPost-approval REMS notification letter Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM251595.pdf. Accessed July 29, 2011.
- US Food and Drug AdministrationDisposal of unused medicines: what you should know Available from: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm. Accessed September 12, 2011.
- US Food and Drug AdministrationQuestions and answers: FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for long-acting and extended-release opioids Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm251752.htm. Accessed July 29, 2011.